SimCorp A/S
Company Announcement no. 04/2021
On February 10, 2021 SimCorp A/S announced a share buyback program in compliance with the provisions of Regulation No. 596/2014 of the European Parliament and of the Council on market abuse (the Market Abuse Regulation - MAR) and delegated legislation under MAR.
In connection with the program SimCorp A/S will repurchase shares for an amount of up to EUR 20.0m, to be executed during the period from February 10, 2021 to July 31, 2021.
The following transactions have been executed under the program:
Date | Number of shares | Average purchase price (DKK per share) | Amount (DKK) |
Accumulated under the program as of last announcement: | 8,700 | 814.75 | 7,088,287 |
February 15, 2021 | 2,600 | 809.77 | 2,105,402 |
February 16, 2021 | 2,800 | 820.70 | 2,297,960 |
February 17, 2021 | 3,000 | 806.60 | 2,419,800 |
February 18, 2021 | 2,800 | 793.87 | 2,222,836 |
February 19, 2021 | 3,000 | 784.96 | 2,354,880 |
Accumulated under the program following above purchases: | 22,900 | 807.39 | 18,489,165 |
Following above purchases, SimCorp holds 724.587 treasury shares corresponding to 1.8% of the share capital.
Purchases for an amount of EUR 17.5m (approx. DKK 130.3m) remain to be executed under the program.
Enquiries regarding this announcement should be addressed to:
Anders Hjort, Head of Investor Relations, SimCorp A/S (+45 3544 8822)
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Zealand Pharma18.7.2025 18:30:00 CEST | Press release
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
SpringWorks Therapeutics, Inc.18.7.2025 17:30:40 CEST | Press release
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
Photocat A/S18.7.2025 17:00:00 CEST | Press release
PHOTOCAT has today applied for a transfer of its trading venue from Nasdaq First North Growth Market to Spotlight Stock Market.
Golden Ocean Group Limited18.7.2025 16:30:00 CEST | Press release
GOGL – Notice of Special General Meeting
Kapitalforeningen SDG Invest18.7.2025 16:06:31 CEST | Pressemeddelelse
Kapitalforeningen SDG Invest - Opdateret prospekt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom